Phui-Ly Liew1, Chun-Sen Hsu2, Wei-Min Liu3, Yu-Chieh Lee4, Yi-Chih Lee5, Chi-Long Chen6. 1. Department of Pathology, Shuang Ho Hospital, Taipei Medical University Taipei, Taiwan ; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan. 2. Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University Taipei, Taiwan. 3. Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei Medical University Taipei, Taiwan. 4. Graduate Institute of Medical Sciences, Taipei Medical University Taipei, Taiwan. 5. Department of International Business, Chien Hsin University of Science and Technology Zhongli City, Taiwan. 6. Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University Taipei, Taiwan ; Department of Pathology, Taipei Medical University Hospital, Taipei Medical University Taipei, Taiwan.
Abstract
OBJECTIVES: Despite considerable interest in the Nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein-1 (Keap1), p16 and epithelial cadherin (E-cadherin) activation in carcinoma progression, contradictory results regarding association of Nrf2/Keap1/E-cadherin and p16 expression with clinico-pathological features and prognosis have been reported. The predictive value of these markers in ovarian carcinoma is unknown. METHODS/MATERIALS: In this retrospective study, 108 cases were evaluated immunohistochemically with antibodies to Nrf2, Keap1, estrogen receptor (ER), p16 and E-cadherin. The results were compared with histological and clinical data, disease-free survival (DFS) and overall survival (OS). RESULTS: A cohort of 108 ovarian carcinomas (47 serous, 23 mucinous, 13 endometrioid and 25 clear cell), including 68 FIGO stage I-II cases and 40 FIGO stage III-IV cases was studied. The age of patients (P=0.005), FIGO stage (P<0.001), immunohistochemical expression of Keap1 (P<0.000), E-cadherin (P=0.045), p53 (P=0.003), p16 (P<0.001) and ER (P=0.004) were significant factors between different histological subtypes. Patients with serous carcinoma were older in age, presented with more advanced stage disease, worst prognosis, highest Keap1 expression and least percentage of E-cadherin immunoreactivity. In univariate analysis, FIGO staging (P=0.000 for DFS; P=0.000 for OS), Nrf2 (P=0.010 for DFS; P=0.001 for OS), and p16 (P=0.004 for DFS; P=0.019 for OS) were associated with worse prognosis. After multivariate analysis, FIGO staging and Nrf2 remained significance prognostic factors. CONCLUSIONS: There were differences in the expression of Nrf2, Keap1, p16 and E-cadherin between different ovarian carcinoma subtypes. In multivariate analysis, FIGO stage and Nrf2 expression were associated with poorer DFS and OS.
OBJECTIVES: Despite considerable interest in the Nuclear factor-erythroid 2-related factor 2 (Nrf2)/Kelch-like ECH-associated protein-1 (Keap1), p16 and epithelial cadherin (E-cadherin) activation in carcinoma progression, contradictory results regarding association of Nrf2/Keap1/E-cadherin and p16 expression with clinico-pathological features and prognosis have been reported. The predictive value of these markers in ovarian carcinoma is unknown. METHODS/MATERIALS: In this retrospective study, 108 cases were evaluated immunohistochemically with antibodies to Nrf2, Keap1, estrogen receptor (ER), p16 and E-cadherin. The results were compared with histological and clinical data, disease-free survival (DFS) and overall survival (OS). RESULTS: A cohort of 108 ovarian carcinomas (47 serous, 23 mucinous, 13 endometrioid and 25 clear cell), including 68 FIGO stage I-II cases and 40 FIGO stage III-IV cases was studied. The age of patients (P=0.005), FIGO stage (P<0.001), immunohistochemical expression of Keap1 (P<0.000), E-cadherin (P=0.045), p53 (P=0.003), p16 (P<0.001) and ER (P=0.004) were significant factors between different histological subtypes. Patients with serous carcinoma were older in age, presented with more advanced stage disease, worst prognosis, highest Keap1 expression and least percentage of E-cadherin immunoreactivity. In univariate analysis, FIGO staging (P=0.000 for DFS; P=0.000 for OS), Nrf2 (P=0.010 for DFS; P=0.001 for OS), and p16 (P=0.004 for DFS; P=0.019 for OS) were associated with worse prognosis. After multivariate analysis, FIGO staging and Nrf2 remained significance prognostic factors. CONCLUSIONS: There were differences in the expression of Nrf2, Keap1, p16 and E-cadherin between different ovarian carcinoma subtypes. In multivariate analysis, FIGO stage and Nrf2 expression were associated with poorer DFS and OS.
Authors: Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang Journal: Cancer Res Date: 2010-06-08 Impact factor: 12.701
Authors: Luisa M Solis; Carmen Behrens; Wenli Dong; Milind Suraokar; Natalie C Ozburn; Cesar A Moran; Alejandro H Corvalan; Shyam Biswal; Stephen G Swisher; B Nebiyou Bekele; John D Minna; David J Stewart; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2010-06-09 Impact factor: 12.531
Authors: Yoo Ri Kim; Ji Eun Oh; Min Sung Kim; Mi Ran Kang; Sang Wook Park; Ji Youn Han; Hyeon Seok Eom; Nam Jin Yoo; Sug Hyung Lee Journal: J Pathol Date: 2010-03 Impact factor: 7.996
Authors: Thiruvengadam Arumugam; Vijaya Ramachandran; Keith F Fournier; Huamin Wang; Lauren Marquis; James L Abbruzzese; Gary E Gallick; Craig D Logsdon; David J McConkey; Woonyoung Choi Journal: Cancer Res Date: 2009-07-07 Impact factor: 12.701
Authors: Emiliano Cocco; Yang Deng; Erik M Shapiro; Ileana Bortolomai; Salvatore Lopez; Ken Lin; Stefania Bellone; Jiajia Cui; Gulden Menderes; Jonathan D Black; Carlton L Schwab; Elena Bonazzoli; Fan Yang; Federica Predolini; Luca Zammataro; Gary Altwerger; Christopher de Haydu; Mitchell Clark; Julio Alvarenga; Elena Ratner; Masoud Azodi; Dan-Arin Silasi; Peter E Schwartz; Babak Litkouhi; W Mark Saltzman; Alessandro D Santin Journal: Mol Cancer Ther Date: 2016-12-12 Impact factor: 6.261
Authors: Marina Rosso; Blanca Majem; Laura Devis; Lara Lapyckyj; María José Besso; Marta Llauradó; María Florencia Abascal; María Laura Matos; Lucia Lanau; Josep Castellví; José Luis Sánchez; Asunción Pérez Benavente; Antonio Gil-Moreno; Jaume Reventós; Anna Santamaria Margalef; Marina Rigau; Mónica Hebe Vazquez-Levin Journal: PLoS One Date: 2017-09-21 Impact factor: 3.240
Authors: Ying-Hui Tong; Bo Zhang; You-You Yan; Yun Fan; Jia-Wen Yu; Si-Si Kong; Dan Zhang; Luo Fang; Dan Su; Neng-Ming Lin Journal: Oncotarget Date: 2017-07-11